To overcome ibrutinib resistance in CLL treatment, several second-generation BTK inhibitors were generated and extensively studied to evaluate their tolerability plus efficacy in patients with R/R CLL (reviewed in (144)). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.